Every Form 4 that Bicara Therapeutics Inc. (BCAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics (BCAX) CEO reported a Form 4 for transactions on October 16, 2025. The executive exercised 24,103 stock options at $3.7898 per share and sold 24,103 common shares at a $18.8259 weighted average price, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the reporting person beneficially owns 309,892 common shares directly and 277,270 derivative securities (options) remain beneficially owned. The sale price ranged from $18.73 to $19.17. The option underlying the exercised shares vests in sixteen equal quarterly installments following August 8, 2023.
Bicara Therapeutics (BCAX) reported insider transactions by its President & COO (also a Director) on 10/15/2025. The officer exercised a stock option for 8,000 shares at an exercise price of $3.7898 and then sold 8,000 shares and an additional 4,500 shares at a weighted average price of $18.1554 (sales occurred between $18.00 and $18.34), executed pursuant to a Rule 10b5‑1 trading plan adopted on February 12, 2025.
Following these transactions, the reporting person beneficially owned 198,141 shares of common stock directly and held 157,334 derivative securities (stock options). The reported option was granted with a term through 08/08/2033 and vests in sixteen equal quarterly installments following 08/08/2023, subject to continued service.
Bicara Therapeutics (BCAX): CEO Form 4 activity. On 10/13/2025 and 10/15/2025, the CEO exercised stock options at $3.7898 per share for 11,445 and 13,289 shares, then sold the same amounts at weighted average prices of $18.9205 and $18.842, respectively. These transactions were executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the trades, the CEO directly owned 309,892 shares. The reported sale prices reflect weighted averages across ranges of $18.73–$19.635 and $18.73–$18.98.
Bicara Therapeutics Inc. Chief Medical Officer David Raben exercised stock options to acquire 22,000 shares of common stock at $3.7898 per share on October 9, 2025, then sold 22,000 shares at $18.45 per share. After these transactions he directly holds 35,497 common shares and continues to hold 128,870 stock options. Footnotes state that a transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025 and describe a vesting schedule for the underlying option grant.
Bicara Therapeutics’ Chief Financial Officer Hyep Ivan exercised stock options for 6,415 shares of common stock at an exercise price of $3.7898 per share on October 9, 2025, and the resulting shares were sold the same day at a weighted-average price of $18.2278 per share in transactions between $18.15 and $18.41. Following these trades, Ivan directly holds 145,355 shares of Bicara common stock. The exercised options are from a grant that vests in sixteen equal quarterly installments beginning August 8, 2023, and the filing notes that a reported transaction was executed under a Rule 10b5-1 trading plan adopted on February 13, 2025.
Bicara Therapeutics Chief Financial Officer Hyep Ivan reported a series of transactions under a Rule 10b5-1 trading plan dated 02/13/2025. Between 10/06/2025 and 10/08/2025 the reporting person acquired option grants exercisable at $3.7898 and sold common stock in multiple trades. After the reported transactions the reporting person beneficially owned 145,355 shares of common stock.
The filings show three option grant vestings/exercises (total underlying shares: 30,385 across the three dates) with an exercise price of $3.7898 and expiration on 08/08/2033. Sales were executed at weighted average prices reported between approximately $18.15 and $18.36, and the filer offered to provide per-trade details on request.
Ryan Cohlhepp, President and COO and a director of Bicara Therapeutics, Inc. (BCAX), reported multiple stock and option transactions executed pursuant to a Rule 10b5-1 trading plan adopted on 02/12/2025. On 10/06/2025 and 10/07/2025, the reporting person acquired options exercisable at $3.7898 and recorded option-based increases of 24,000 and 8,000 option rights. Offsetting sales were reported across the same dates totaling 50,500 common shares sold at weighted-average prices around $18.06. Following these transactions the reporting person beneficially owned 202,641 shares of common stock. The Form 4 discloses that vesting of the option shares occurs in sixteen quarterly installments following 08/08/2023.
Lara Meisner, Chief Legal Officer of Bicara Therapeutics (BCAX), reported option exercise and an immediate sale on 09/29/2025 under a pre-established plan. The reporting person exercised a stock option with a $9.2435 exercise price to acquire 33,807 shares and concurrently sold 33,807 shares at $14.75 per share, leaving 0 shares of common stock held directly after the sale. The option granting those shares vests on a schedule that began with a 25% vesting on 08/13/2025 and continues in twelve equal quarterly installments; the option expires 08/13/2034. The filing notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted November 13, 2024.